Ductal hyperplasia is an overgrowth of cells lining the milk ducts of the breast. It is not cancer, but it sits on a spectrum of breast changes that can, in some cases, slightly increase the risk of developing breast cancer later in life. If you’ve seen this term on a biopsy report, it helps to understand that ductal hyperplasia comes in two distinct forms, each with a different level of risk and a different path forward.
Two Types: Usual vs. Atypical
The cells lining your breast ducts normally grow in a thin, orderly layer. In ductal hyperplasia, those cells multiply beyond what’s needed, creating extra layers inside the duct. Pathologists divide this into two categories based on how the extra cells look under a microscope.
Usual ductal hyperplasia (UDH) means the extra cells, while more numerous than normal, still look varied and relatively disorganized, much like normal breast cells. They differ in size and shape from one another. UDH is the more common and less concerning form.
Atypical ductal hyperplasia (ADH) means the extra cells have started to take on a more uniform, identical appearance. They may arrange themselves into recognizable patterns, such as small round spaces or solid clusters, that pathologists associate with early precancerous changes. ADH shares some features with a condition called ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer, but doesn’t fully meet the criteria. One key distinction is size: DCIS typically involves two or more ductal units and measures larger than 2 millimeters, while ADH falls below that threshold.
How Ductal Hyperplasia Is Found
Most people never feel ductal hyperplasia. It doesn’t form a lump you can detect on your own. Instead, it’s almost always discovered during a routine mammogram or a mammogram done for another reason. Clustered microcalcifications, tiny white specks of calcium visible on imaging, are the most common mammographic finding that leads to the discovery of ductal hyperplasia. These calcifications can look similar to those seen with small cancers, which is why a biopsy is needed to tell the difference.
Atypical ductal hyperplasia is more likely to show a visible correlation on a mammogram than other forms of atypical growth. In one study, mammographic abnormalities could be directly matched to the hyperplasia in about 48% of ADH cases. Still, there’s no single imaging appearance that definitively identifies hyperplasia. The mammogram raises the question; the biopsy answers it.
Breast Cancer Risk for Each Type
One of the first things people want to know after a ductal hyperplasia diagnosis is what it means for their cancer risk. The answer depends heavily on which type you have.
Usual ductal hyperplasia carries a modest increase. Women with UDH on a benign biopsy have roughly 1.5 to 2 times the breast cancer risk of the general population. To put that in perspective, if the average woman’s lifetime risk is about 12%, UDH might raise it to somewhere around 18 to 24%. That’s a real increase, but a relatively small one in absolute terms.
Atypical ductal hyperplasia carries a more significant increase. A large study published in JAMA Oncology found that women with ADH had a cumulative risk of developing invasive breast cancer of about 5.7% over ten years, roughly 2.6 times the risk of women without ADH. The risk was somewhat higher (6.7% at ten years) for women whose ADH was found through a surgical biopsy compared to those diagnosed by needle biopsy (5% at ten years), likely because surgical biopsies sample more tissue and can better characterize the extent of the changes.
It’s worth noting that this elevated risk applies to both breasts, not just the one where the hyperplasia was found. That suggests ductal hyperplasia reflects a broader tendency in breast tissue rather than a localized problem that might “turn into” cancer at that exact spot.
What Happens After an ADH Diagnosis
If a core needle biopsy returns a diagnosis of atypical ductal hyperplasia, the current standard recommendation is surgical excision. This isn’t because ADH itself is dangerous. It’s because a needle biopsy samples only a small portion of the area, and roughly 20% to 30% of ADH lesions found this way are “upgraded” to cancer (either DCIS or invasive cancer) once a surgeon removes the full area and a pathologist examines all of it. The surgical excision is both diagnostic and therapeutic: it removes the questionable tissue and provides a definitive answer about what’s there.
The procedure is typically a lumpectomy-style outpatient surgery. Recovery is usually straightforward, with most people returning to normal activities within a week or two. If the excision confirms that ADH was the most advanced finding, no further surgery is needed.
For usual ductal hyperplasia, surgical excision is generally not recommended. UDH is considered a benign finding, and routine follow-up with standard screening is the typical approach.
Risk Reduction Options for ADH
Because atypical ductal hyperplasia places you in a higher-risk category, your doctor may discuss medications that can lower your future breast cancer risk. Two commonly used options are tamoxifen and raloxifene, both of which work by blocking estrogen’s effects on breast tissue. Tamoxifen can reduce the risk of invasive breast cancer by about 50% in high-risk women, while raloxifene reduces it by about 38%. Both also lower the risk of non-invasive breast cancer like DCIS.
These medications do come with their own side effects, so the decision to take them involves weighing the benefit against those trade-offs. Not everyone with ADH chooses preventive medication, and the decision is a personal one made in the context of your overall health and risk profile.
Ongoing Monitoring After Diagnosis
After a diagnosis of atypical ductal hyperplasia, closer surveillance becomes part of your routine. While the exact schedule can vary, current evidence supports diagnostic mammograms every six months for at least the first two years. After that initial period of closer monitoring, many women transition to annual mammograms, sometimes supplemented with breast MRI depending on their overall risk level.
For usual ductal hyperplasia, the follow-up is less intensive. Standard annual mammography screening is generally sufficient, though your doctor may adjust this based on other risk factors like family history.